83732-68-7

Basic information

• Product Name: 2,3-dichloro-6-methoxypyridine
• Synonyms: Einecs 280-618-7;Pyridine, 2,3-dichloro-6-methoxy-
• CAS NO: 83732-68-7
• Molecular Formula: C₆H₅Cl₂NO
• Molecular Weight: 178.02
• EINECS: 280-618-7
• Mol File: 83732-68-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 219℃
• Flash Point: 86℃
• Appearance: /
• Density: 1.363
• Vapor Pressure: 0.184mmHg at 25°C
• Refractive Index: 1.537
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.37±0.10(Predicted)
• CAS DataBase Reference: 2,3-dichloro-6-methoxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-dichloro-6-methoxypyridine(83732-68-7)
• EPA Substance Registry System: 2,3-dichloro-6-methoxypyridine(83732-68-7)

Safety Data

• Hazardous Substances Data: 83732-68-7(Hazardous Substances Data)

Usage

General Description

2,3-Dichloro-6-methoxypyridine is a chemical compound with the molecular formula C6H5Cl2NO. It is a chlorinated derivative of pyridine, with two chlorine atoms and one methoxy group attached to the pyridine ring. 2,3-Dichloro-6-methoxypyridine is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals due to its high reactivity and versatility. It can be prepared through the reaction of 2,3-dichloropyridine with methanol, and it is often used as a building block in the production of insecticides, fungicides, and other agricultural chemicals. Its chemical structure and reactivity make it a valuable component in the development of new drug molecules and crop protection products.

InChI:InChI=1/C6H5Cl2NO/c1-10-5-3-2-4(7)6(8)9-5/h2-3H,1H3

Upstream product

• 742070-73-1 3-chloro-6-methoxypyridin-2-amine 
• 38533-61-8 2-chloro-6-methoxy-3-nitropyridine 
• 17228-64-7 6-chloro-2-methoxypyridine 
• 34392-85-3 3-amino-2-chloro-6-methoxypyridine 

Downstream Products

• 24525-63-1 2,3-Dichloro-6-hydroxypyridin 
• 1019849-78-5 1-(3-chloro-6-methoxy-pyridin-2-yl)-3-(R)-methyl-piperazine 

Relevant articles and documents

Development of a safe and scalable route towards a tau PET tracer precursor

A scalable 5-step synthesis of the diazacarbazole derivative 1 used as tau PET tracer precursor is reported. Key features of this synthesis include a Buchwald-Hartwig amination, a Pd catalyzed C–H activation and a Suzuki-Miyaura cross-coupling.

9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS

The present invention relates to a 9-azabicyclo[3.3.1]nonane derivative of formula (I), wherein R1 is H or C1-5alkyl; X is O or NR2, wherein R2 is H, C1-5alkyl or C2-5acyl and Ar is C6-10aryl or a 5-10 membered heteroaryl ring system, both being optionally substituted with one to three of R3-R5 independently selected from halogen, C1-5alkyl, C1-5alkoxy, C3-6cycloalkyl, C2-5alkenyl, C2-5alkynyl, CN, NO2, hydroxy, phenyl, phenoxy and phenylC1-2alkoxy, wherein said C1-5alkyl and C1-5alkoxy are optionally substituted with one to three halogens and wherein said phenyl, phenoxy and phenylC1-2alkoxy are optionally substituted with one to three substituents independently selected from halogen and methyl or two of R3-R5 at adjacent positions together form a methylenedioxy or propylene unit, with the proviso that the compounds exo-9-methyl-3-phenoxy-9-azabicyclo[3.3.1]nonane and N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1H indazole-5-amine are excluded, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 9-azabicyclo[3.3.1]nonane derivatives and to their use in therapy.

BIARYL PIPERAZINYL-PYRIDINE ANALOGUES

Biaryl piperazinyl -pyri dine analogues are provided, of the Formula (I): wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands, for receptor localization studies.